immunization

(redirected from Active immunization)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.

Immunization

The construction of an asset and a liability match that benefits from offsetting changes in value.

Price Immunization

A strategy of matching assets to future liabilities. That is, price immunization involves investing in certain securities with a certain expected return so that the investor will be able to pay for future liabilities. Pension funds and annuities use price immunization more than many investors because they have future liabilities that are both large and relatively easy to estimate. Portfolios that practice price immunization usually invest in low-risk, investment-grade securities. See also: Portfolio dedication.

immunization

A technique of investing in bonds such that the portfolio's target return is protected against interest rate fluctuations. Changes in returns at which cash flows can be reinvested are offset by changes in the value of the securities in the portfolio. See also bullet immunization.
References in periodicals archive ?
However, once these were eliminated over a period of another 3 months, active immunization was unable to confer sustained protection at 7 months.
In the European Union, Prevenar 13 is indicated for active immunization for the prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae in adults aged 50 years and older caused by 13 Streptococcus pneumoniae serotypes.
About Fluzone Intradermal Quadrivalent (Influenza Vaccine) Indication Fluzone Intradermal Quadrivalent vaccine is indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
In the United States, Prevnar 13 is indicated in adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F).
Vaccination aims for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup C.
The vaccine is for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae.
The approval is for active immunization against influenza disease caused by the H5N1 A/Vietnam/1203/2004 influenza virus in adults aged 18-64 who may be at an increased risk of exposure to the H5N1 influenza virus.
Food and Drug Administration (FDA) under an accelerated approval pathway for adults 50 years of age and older for active immunization for the prevention of pneumococcal pneumonia and invasive disease caused by the 13 serotypes contained in the vaccine.
Tenders are invited for Vaccination has to prevent the goal by active immunization of damage induced by Neisseria meningitidis serogroup C meningitis.
Intellect's has incorporated proprietary safety features into its ANTISENILIN(R) monoclonal antibody and RECALL-VAXTM technology platforms for both passive and active immunization, respectively to minimize the potential for adverse side-effects by generating antibodies that bind only the toxic beta amyloid and not the Amyloid Precursor Protein.
An injectable influenza vaccine approved for active immunization of adults ages 18 and older against influenza disease caused by influenza virus subtypes A and B contained in the vaccine.